Article Per Year (5 Year)
p-Index From 2021 - 2026
2.808
P-Index
This Author published in this journals
All Journal Media Kesehatan Masyarakat Indonesia Jurnal Ilmu Kedokteran (Journal of Medical Science) Majalah Kedokteran Bandung Jurnal Kesehatan Melayu JURNAL SIMETRIK Spektra: Jurnal Fisika dan Aplikasinya Pendas : Jurnah Ilmiah Pendidikan Dasar Indonesian Journal of Obstetrics & Gynecology Science Jurnal Surya Masyarakat Acta Biochimica Indonesiana Journal Of Widya Medika Junior Care : Jurnal Ilmiah Ilmu Kesehatan INDONESIAN JOURNAL OF MEDICAL LABORATORY SCIENCE AND TECHNOLOGY Jurnal Surya Masyarakat Jurnal Pengabdian kepada Masyarakat Nusantara Unri Conference Series: Community Engagement Narra J Prosiding Konferensi Nasional PKM-CSR jabdimasunipem Jurnal Natur Indonesia Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal)
Arfianti Arfianti
Departemen Biologi Kedokteran Fakultas Kedokteran Universitas Riau
Religion Aerospace Engineering Agriculture, Biological Sciences & Forestry Humanities Automotive Engineering Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Computer Science & IT Control & Systems Engineering Decision Sciences, Operations Research & Management Dentistry Earth & Planetary Sciences Economics, Econometrics & Finance Education Electrical & Electronics Engineering Energy Engineering Environmental Science Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Materials Science & Nanotechnology Medicine & Pharmacology Nursing Physics Public Health Social Sciences Other

Published : 27 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Narra J

 1 
Unveiling the impacts of metformin on hepatocellular carcinoma: A bioinformatic exploration in cell lines Soraya, Soraya; Arfianti, Arfianti; Adikusuma, Wirawan; Irham, Lalu M.; Hamidy, Muhammad Y.; Winarto, Winarto; Rangkuti, Ina F.; Darmawi, Darmawi
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.968

Abstract

The most common type of liver cancer is hepatocellular carcinoma (HCC), accounting for 75–85% of cases. Despite its associated side effects, sorafenib remains the standard treatment for HCC. Given the critical need to improve therapeutic efficacy while minimizing adverse effects, alternative drugs must be thoroughly investigated. Numerous studies indicate that combining sorafenib with metformin results in a more favorable treatment profile. The aim of this study was to employ bioinformatics methodologies to elucidate the molecular pathways and genetic underpinnings of metformin's efficacy in HCC treatment. Genes associated with metformin and its action against HCC (Huh-7 and HepG2 cells) were acquired from the NCBI-GEO data collection by utilizing pre-determined keywords. Subsequently, pathways implicated in metformin-mediated HCC treatment were analyzed through the Kyoto Encyclopedia of Genes and Genomes (KEGG). Our analysis revealed the involvement of multiple pathways, with metabolic pathways implicated in 80% of the total cases. Neurodegenerative pathways were involved in only around 60% of the total cases. These findings align with the multifaceted mechanisms of metformin’s action, encompassing adenosine monophosphate-activated protein kinase activation, apoptosis induction, insulin regulation, anti-inflammatory responses, and modulation of cell proliferation. This comprehensive investigation sheds light on the intricate molecular landscape underpinning metformin's therapeutic efficacy in HCC, thereby informing potential avenues for optimizing treatment strategies.
Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia Djojosugito, Fauzia A.; Arfianti, Arfianti; Wisaksana, Rudi; Siregar, Fajri M.; Nasronudin, Nasronudin; Rachman, Brian E.; Khairunisa, Siti Q.; Indrati, Agnes R.
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.1022

Abstract

Indonesia has one of the highest HIV infection rates in Southeast Asia. The use of dolutegravir, an integrase strand transfer inhibitor (INSTI), as a first-line treatment underscores the need for detailed data on INSTI drug resistance mutations (DRMs). Currently, there is a lack of comprehensive data on DRMs INSTI and other HIV drug resistance in Indonesian patients, both pre- and post-treatment. The aim of this study was to identify the subtypes and drug resistance mutations of the protease, reverse transcriptase, and integrase genes in both treatment-naive and ARV-treated patients in Bandung, West Java, Indonesia. A cross-sectional study was conducted involving HIV-positive patients at Hasan Sadikin Hospital, Bandung, Indonesia, from September 2022 to January 2023. The patients were categorized into two groups: ARV-treated and pre-treatment patients. Peripheral blood mononuclear cells (PBMCs) were processed for DNA extraction, followed by amplification and sequencing of the pol gene to detect mutations and subtypes. The study found that the predominant subtype was CRF01_AE, accounting for 85.4% and 69% of pre-treatment and treated patients, respectively, followed by recombinant forms such as A1/CRF01_AE, CRF01_AE/CRF02_AG, subtype B, and other subtypes. Among ARV-treated/INSTI-naive patients, major INSTI DRMs R263K and Y143H were identified, while pre-treatment patients exhibited accessory integrase DRMs. The most common DRMs detected were non-nucleoside reverse transcriptase inhibitor (NNRTI) DRMs, with prevalences of 14.6% and 7% in pre-treatment and ARV-treated patients, respectively. In conclusion, CRF01_AE emerged as the predominant subtype in both pre-treatment and ARV-treated patients in Bandung, underscoring the necessity for ongoing surveillance of integrase DRMs, particularly given the presence of major INSTI DRMs in patients undergoing INSTI treatment.
Co-Authors Andi Zainal Ardini, Nadiah Yamanza Ariza Julia Paulina Armi, Wahyuli Bayu Fajar Pratama Bebe Gani Dani Rosdiana Darmawi Darmawi Dedi Afandi Deyana, Frilly Dita Kartika Sari Djojosugito, Fauzia A. Elda Nazriati Erika Erika Fauzan A. Sangadji Fauzia Andrini Fifia Chandra Fifia Chandra Hamidy, Muhammad Y. Hendra Asputra Hendri, Sherin Alifia Huriatul Masdar Ibrahim, Sundus Idawati Idawati Idawati Indrati, Agnes R. Irham, Lalu M. Ismawati Ismawati Ismawati ismawati Kesumah, Dewi Iramayana Sandra Khairunisa, Siti Q. Labecka, Magda Lazuardi Umar Maisaroh Maisaroh Muhammad Beni Septima Muhammad Nawir Muhammad Nawir Nababan, Heru Maranatha Nasronudin Nasronudin Nukman Moeloek Nurfi Pratiwi, Nurfi Nurul Humairah Arfiza Pernantah, Piki Setri Purnomo Soeharso Rachman, Brian E. Rahmat Azhari Kemal Rahmondia N. Setiadi Ramadhani, Nur'aina ID Rangkuti, Ina F. Reni Oktora Riefni Silara Dini Rina Amtarina Rita Endriani Rudi Wisaksana S, Donel S.Pd. M Kes I Ketut Sudiana . Saputra, Nicko Pisceski Kusika Sherin Alifia Hendri Simanjuntak, Arya Marganda Siregar, Fajri M. Soraya Soraya Suri Dwi Lesmana Suyanto Taihuttu, Felix TB Odih Rhomdani Wahid Tetty M Linda Tri Muhti Puja Kesuma Ulfah Ulfah Ulfah Ulfah Winarto Winarto Winarto Winarto Wirawan Adikusuma Yuhendri, Vitriyanna Mutiara Yulia Irvani Dewi Yulia Wardany Yuliati Yuliati Zarfiardy Aksa Fauzi